Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates

Core Viewpoint - Clene Inc. reported a quarterly loss of $0.85 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.60, indicating a significant earnings surprise of -41.67% [1] Financial Performance - The company posted revenues of $0.02 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 81.25%, and a decline from $0.09 million in the same quarter last year [2] - Over the last four quarters, Clene has only surpassed consensus EPS estimates once [2] Stock Performance - Clene shares have increased by approximately 77.2% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Future Outlook - The company's earnings outlook will be crucial for investors, particularly in terms of consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$0.48 on revenues of $0.09 million, and for the current fiscal year, it is -$2.10 on revenues of $0.31 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Clene belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8]